Flibanserin: A potential treatment for Hypoactive Sexual Desire Disorder in premenopausal women

Women's Health

Volumn 6, Issue 5, 2010, Pages 639-653

  Clayton, A H ^a   Dennerstein, L ^b   Pyke, R ^c   Sand, M ^c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

5 HT1A agonist; 5 HT2A antagonist; Female Sexual Dysfunction; flibanserin; Hypoactive Sexual Desire Disorder

Indexed keywords

AMFEBUTAMONE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FLIBANSERIN; PAROXETINE; PLACEBO; SIMVASTATIN; TESTOSTERONE;

ANXIETY; AREA UNDER THE CURVE; BEDTIME DOSAGE; CLINICAL TRIAL; COGNITIVE THERAPY; CONSTIPATION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG EXPOSURE; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FIRST PASS EFFECT; FOOD; FOOD DRUG INTERACTION; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOACTIVE SEXUAL DESIRE DISORDER; HYPOTENSION; INSOMNIA; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; PRURITUS; PSYCHOSEXUAL DISORDER; REVIEW; SEDATION; SIDE EFFECT; SINUSITIS; SLEEP DISORDER; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

BENZIMIDAZOLES; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; LIBIDO; PREMENOPAUSE; SEROTONIN AGENTS; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

EID: 77957736604     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.10.54     Document Type: Review

References (57)

1. American Psychiatric Association: DSM-IV: Diagnostic and Statistical Manual of Mental Disorders (4th Edition). Text revision. American Psychiatric Press, Washington, DC, USA (2000).
2. Hatzichristou D, Rosen RC, DeRogatis LR et al.: Recommendations for the clinical evaluation of men and women with sexual dysfunction. J. Sex. Med. 7(1-2), 337-348 (2010).
3. Clayton AH, Goldfscher ER, Goldstein I, DeRogatis L, Lewis-DAgostino DJ, Pyke R: Validation of the Decreased Sexual Desire Screener (DSDS): a brief diagnostic instrument for generalized acquired female Hypoactive Sexual Desire Disorder (HSDD). J. Sex. Med. 6(3), 730-738 (2009).
4. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB: Sexual problems and distress in United States women: prevalence and correlates. Obstet. Gynecol. 112(5), 970-978 (2008).
5. Dennerstein L, Koochaki P, Barton I, Graziottin A: Hypoactive Sexual Desire Disorder in menopausal women: a survey of western European women. J. Sex. Med. 3(2), 212-222 (2006).
6. Dennerstein L, Hayes R, Sand M, Lehert P: Attitudes toward and frequency of partner interactions among women reporting decreased sexual desire. J. Sex. Med. 6(6), 1668-1673 (2009).
7. Graziottin A, Koochaki PE, Rodenberg CA, Dennerstein L: The prevalence of Hypoactive Sexual Desire Disorder in surgically menopausal women: an epidemiological study of women in four European countries. J. Sex. Med. 6(8), 2143-2153 (2009).
8. Rosen RC, Shifren JL, Monz BU, Odom DM, Russo PA, Johannes CB: Correlates of sexually related personal distress in women with low sexual desire. J. Sex. Med. 6(6), 1549-1560 (2009).
9. Biddle AK, West SL, DAloisio AA, Wheeler SB, Borisov NN, Thorp J: Hypoactive Sexual Desire Disorder in postmenopausal women: quality of life and health burden. Value Health 12, 763-772 (2009).
10. Revicki D, Fisher W, Rosen R, Kuppermann M, Margolis MK, Hanes V: The impact of Hypoactive Sexual Desire Disorder (HSDD) on women and their relationships: qualitative data from patient focus groups. J. Sex. Med. 7(Suppl. 3), 124-125 (2010).
11. Kingsberg SA: Identifying HSDD in the family medicine setting. J. Fam. Pract. 58(Suppl. 7), S22-S25 (2009).
12. Harsh V, McGarvey EL, Clayton AH: Physician attitudes regarding Hypoactive Sexual Desire Disorder in a primary care clinic: a pilot study. J. Sex. Med. 5(3), 640-645 (2008).
13. Parish SJ, Clayton AH: Sexual medicine education: review and commentary. J. Sex. Med. 4(2), 259-267 (2007).
14. Abdolrasulnia M, Shewchuk RM, Roepke N et al.: Management of female sexual problems: perceived barriers, practice patterns, and confdence among primary care physicians and gynecologists. J. Sex. Med. 7(7), 2499-2508 (2010).
15. Brotto LA, Bitzer J, Laan E, Leiblum S, Luria M: Women's sexual desire and arousal disorders. J. Sex. Med. 7(1 Pt 2), 586-614 (2010).
16. McCabe MP: Evaluation of a cognitive behavior therapy program for people with sexual dysfunction. J. Sex. Marital Ther. 27(3), 259-271 (2001).
17. Trudel G, Marchland A, Ravart M, Aubin S, Turgeon L, Fortier P: The effect of a cognitive-behavioral group treatment program on hypoactive sexual desire in women. Sex. Rel. Ther. 16(2), 145-164 (2001).
18. McCabe M, Althof SE, Assalian P et al.: Psychological and interpersonal dimensions of sexual function and dysfunction. J. Sex. Med. 7(1-2), 327-336 (2010).
19. Writing Group for the Women's Health Initiative Investigators: Risks and benefts of estrogen plus progestin in healthy postmenopausal women. JAMA 288(3), 321-333 (2002).
20. Wierman ME, Nappi RE, Avis N et al.: Endocrine aspects of women's sexual function. J. Sex. Med. 7(1-2), 561-585 (2010).
21. Nachtigall L, Casson P, Lucas J, Schofeld V, Melson C, Simon J: The safety and tolerability of the transdermal testosterone patch for up to 4 years in surgically menopausal women on estrogen/progestin therapy. J. Sex. Med. 7(Suppl. 3), 142 (2010).
22. Shifren JL, Johannes CB, Monz BU, Russo PA, Bennett L, Rosen R: Help-seeking behavior of women with self-reported distressing sexual problems. J. Womens Health (Larchmt.) 18(4), 461-468 (2009).
23. Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S: Pharmacology of fibanserin. CNS Drug Rev. 8(2), 117-142 (2002).
24. Marazziti D, Palego L, Giromella A et al.: Region-dependent effects of fibanserin and buspirone on adenylyl cyclase activity in the human brain. Int. J. Neuropsychopharmacol. 5(2), 131-140 (2002).
25. Allers KA, Dremencov E, Ceci A et al.: Acute and repeated fibanserin administration in female rats modulates monoamines differentially across brain areas: a microdialysis study. J Sex. Med. 7, 1757-1767 (2010).
26. Pfaus JG: Pathways of sexual desire. J. Sex. Med. 6(6), 1506-1533 (2009).
27. Kennedy S: Flibanserin: initial evidence of effcacy on sexual dysfunction in patients with Major Depressive Disorder. J. Sex. Med. (2010) (Epub ahead of print).
28. McGahuey CA, Gelenberg AJ, Laukes CA et al.: The Arizona Sexual Experiences Scale (ASEX): reliability and validity J. Sex. Marital Ther. 26(1), 25-40 (2000).
29. Rosen R, Brown C, Heiman J et al.: The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J. Sex. Marital Ther. 26(2), 191-208 (2000).
30. Clayton AH, McGarvey EL, Clavet GJ: The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol. Bull. 33(4), 731-745 (1997).
31. Sills T, Wunderlich G, Pyke R et al.: The Sexual Interest and Desire Inventory-Female (SIDI-F): item response analyses of data from women diagnosed with Hypoactive Sexual Desire Disorder. J. Sex. Med. 2(6), 801-818 (2005).
32. US Department of Health, Education and Welfare: Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology (Revised Edition). Guy W (Ed.). MD, USA 216-222 (1976).
33. Clayton A, Jayne C, Jacobs M, Kimura T, Pyke R, Lewis-DAgostino D: Effcacy of fibanserin as a potential treatment for Hypoactive Sexual Desire Disorder in North American premenopausal women: results from the DAHLIA trial. J. Sex. Med. 6(Suppl. 5), 408-420 (2009).
34. Jolly E, DeRogatis L, Komer L et al.: Effcacy of fibanserin as a potential treatment for Hypoactive Sexual Desire Disorder in North American premenopausal women: results from the VIOLET trial. J. Sex. Med. 6(Suppl. 5), 466 (2009).
35. Thorp J, Simon J, Dattani D et al.: Effcacy of fibanserin as a potential treatment for Hypoactive Sexual Desire Disorder in North American premenopausal women: results from the DAISY trial. J. Sex. Med. 6(Suppl. 5), 425 (2009).
36. Nappi R, Dean J, van Lunsen H, Hebert A, Kimura T, Pyke R: Effcacy of fibanserin as a potential treatment for Hypoactive Sexual Desire Disorder in European premenopausal women: results from the ORCHID trial. J. Sex. Med. 6(Suppl. 5), 409 (2009).
37. Goldfscher E, Cotton D, Mikl J, Pyke R, Sand M: Effcacy of continued fibanserin treatment on sexual desire and satisfying sexual events in premenopausal women with HSDD: results from the ROSE study. J. Sex. Med. 5(Suppl. 3), 159 (2008).
38. Goldfscher E, Cotton D, Mikl J, Pyke R, Sand M: Effcacy of continued fibanserin treatment on distress associated with sexual dysfunction in premenopausal women with HSDD: results from the ROSE study. J. Sex. Med. 5(Suppl. 3), 174 (2008).
39. Goldfscher E, Cotton D, Mikl J, Pyke R, Sand M: Effcacy of continued fibanserin treatment on sexual functioning in premenopausal women with HSDD: results from the ROSE study. J. Sex. Med. 5(Suppl. 3), 159 (2008).
40. Pyke R, Goldfscher E, Mikl J: Safety and tolerability of fibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from the ROSE study. Presented at: American Psychiatric Association 2008 Annual Meeting. Washington, DC, USA (2008).
41. Jolly E, Clayton AH, Thorp J, Nappi R, Kimura T, Pyke R: Design of randomized controlled trials of fibanserin in premenopausal women with Hypoactive Sexual Desire Disorder. J. Sex. Med. 6(Suppl. 5), 465 (2009).
42. Soules MR, Sherman S, Parrott E et al.: Executive summary: Stages of Reproductive Aging Workshop (STRAW). Climacteric 4(4), 267-272 (2001). (Pubitemid 34002968)
43. DeRogatis L, Clayton A, Lewis DAgostino D, Wunderlich G, Fu Y: Validation of the Female Sexual Distress Scale-Revised for assessing distress in women with Hypoactive Sexual Desire Disorder. J. Sex. Med. 5(2), 357-364 (2008).
44. Clayton AH, Segraves RT, Leiblum S et al.: Reliability and validity of the Sexual Interest and Desire Inventory-Female (SIDI-F), a scale designed to measure severity of female Hypoactive Sexual Desire Disorder. J. Sex. Marital Ther. 32(2), 115-135 (2006).
45. Lewis-DAgostino D, Clayton AH, Wunderlich G, Kimura T, DeRogatis L, Goldstein A: Validating the Sexual Interest and Desire Inventory-Female (SIDI-F) in North American women. Obstet. Gynecol. 109(Suppl. 4), S23 (2008).
46. Nappi R, van Lunsen HW, Tignol J, Goldmeier D, Pyke R, Staehle H: Validation of the Sexual Interest and Desire Inventory-Female© (SIDI-F©) in European Women. J. Sex. Med. 5(Suppl. 2), 53 (2008).
47. Althof SE, Rosen RC, DeRogatis L, Corty E, Quirk F, Symonds T: Outcome measurement in Female Sexual Dysfunction clinical trials: review and recommendations. J. Sex. Marital. Ther. 31, 153-166 (2005).
48. DeRogatis LR, Rosen R, Leiblum S, Burnett A, Heiman J: The Female Sexual Distress Scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women. J. Sex. Marital Ther. 28(4), 317-330 (2002).
49. Wiegel M, Meston C, Rosen R: The Female Sexual Function Index (FSFI): cross-validation and development of clinical cutoff scores. J. Sex. Marital Ther. 31(1), 1-20 (2005).
50. Gerstenberger EP, Rosen RC, Brewer JV et al.: Sexual desire and the Female Sexual Function Index (FSFI): a sexual desire cutpoint for clinical interpretation of the FSFI in women with and without Hypoactive Sexual Desire Disorder. J. Sex. Med. (2010) (Epub ahead of print).
51. Clayton AH, Dennerstein L, Fisher WA, Kingsberg SA, Perelman MA, Pyke RE: Standards for clinical trials in sexual dysfunction in women: research designs and outcomes assessment. J. Sex. Med. 7(1-2), 541-560 (2010).
52. Jolly E, Clayton AH, Thorp J et al.: Effcacy of fibanserin 100 mg qhs as a potential treatment for Hypoactive Sexual Desire Disorder in premenopausal women. J. Sex. Med. 6(Suppl. 5), 465 (2009).
53. Jolly E, Clayton AH, Thorp J, Kimura T, Sand M, Pyke R: Effcacy of fibanserin 100 mg qhs as a potential treatment for Hypoactive Sexual Desire Disorder in North American premenopausal women. J. Sex. Med. 6(Suppl. 5), 465 (2009).
54. Jolly E, Thorp JM, Clayton AH, Kimura T, Pyke R: Patient's perspective of effcacy of fibanserin in premenopausal women with HSDD. J. Sex. Med. 7, 133-134 (2010).
55. Clayton AH, Jolly E, Thorp JM et al.: Effcacy of fibanserin 100 mg qhs in premenopausal women with Hypoactive Sexual Desire Disorder: responder analyses. J. Sex. Med. 7(Suppl. 3), 122 (2010).
56. Jolly E, Clayton AH, Thorp J et al.: Safety and tolerability of fibanserin in premenopausal women with Hypoactive Sexual Desire Disorder. J. Sex. Med. 6(Suppl. 5), 409 (2009).
57. The 3rd International Consultation on Sexual Medicine (ICSM): International Consultation on Urological Diseases and the International Society for Sexual Medicine (ISSM). J. Sex Med. 7, 1-2 (2010).